Study summary

Sac-TMT shrank tumors in nearly half of heavily treated patients

OptiTROP-Breast01 trial (sac-TMT) · 263 people, phase 3 · Published April 2025, Nature Medicine

6.7months without progression, vs 2.5 with chemotherapy

What was tested

Sacituzumab tirumotecan (sac-TMT), another TROP2 antibody-drug conjugate, against chemotherapy after two or more earlier treatments. Run in China.

What they found

What it means

Merck is now testing sac-TMT worldwide, including after surgery.

Nat Med, via PubMed ↗ Trial record NCT05347134 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.